Tyrosine Kinase Inhibitors in DyplAsia of Lung Epithelium
Phase of Trial: Phase II
Latest Information Update: 23 Aug 2016
At a glance
- Drugs Gefitinib (Primary)
- Indications Head and neck cancer; Non-small cell lung cancer; Precancerous conditions
- Focus Therapeutic Use
- Acronyms TIDAL1
- 29 Apr 2016 Planned End Date changed from 1 Dec 2016 to 1 Jun 2016.
- 29 Apr 2016 Status changed from recruiting to discontinued.
- 19 Oct 2015 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov record.